Inside Salk; Salk Insitute
Home > News & Press > InsideSalk > 01|14 Issue > Salk Institute Board of Trustees Elects Three Visionary Business Leaders

Salk Institute Board of Trustees Elects Three Visionary Business Leaders

Board of Trustees

From left: Elizabeth "Liz" Keadle, David F. Hale and Alan D. Gold

The Salk Institute is pleased to announce that Elizabeth Keadle, David F. Hale, and Alan D. Gold have been elected to its Board of Trustees.

"Liz, Alan and David each bring outstanding records of entrepreneurial success and business expertise to Salk," said Irwin M. Jacobs, Chairman of the Salk Institute Board of Trustees. "We are greatly pleased to have them join our Board of Trustees."

Elizabeth "Liz" Keadle is an alumna of the Institute and worked in the Peptide Biology Laboratory with Salk scientist Wylie Vale while a student at UC San Diego. She started as a volunteer and was hired to work on several research projects, including Vale's work with corticotropin-releasing factor, which his group discovered in 1981. Her experience at Salk led to a career in the biotech business; she eventually joined Swedish biotech supply company Pharmacia AB, where she rose to key technical and business leadership positions. She also became involved in the launch of the local biotech company Invitrogen, which quickly grew to become the world's largest biotech research supply company and went public in 1999. Years later, it was renamed Life Technologies and in 2013 was sold to Thermo-Fisher for $13.6 billion. An ardent supporter of Salk science, Keadle is a longtime Symphony at Salk sponsor and created an endowment in support of the Vale lab. She recently established the Wylie Vale Chair as a lasting legacy to honor the late scientist; Paul Sawchenko, professor and head of Salk's Laboratory of Neuronal Structure and Function, currently holds the chair.

David F. Hale is chairman and chief executive officer of Hale BioPharma Ventures, LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic, and medical device companies. He also serves as executive chairman of Biocept, Inc., a cancer diagnostic company working on the detection and analysis of circulating tumor cells. Previously, he was president and chief executive officer of CancerVax Corporation from October 2000 through its merger in May 2006 with Micromet, Inc., where he served as chairman until its acquisition by Amgen Inc. in 2012. Additionally, Mr. Hale is chairman of Santarus, Inc., and a founding director and chairman of Conatus Pharmaceuticals, Inc. He is a co-founder and chairman of numerous other companies. Mr. Hale currently serves on the board of directors of BIOCOM, which he co-founded, and the San Diego Economic Development Corporation. He is a former member of the board of the Biotechnology Industry Organization (BIO) and the Biotechnology Institute. He is a co-founder and a director of CONNECT, acts as chairman of the board of trustees of Rady Children's Hospital, and is a member of Rady School of Management Dean's Advisory Council.

Alan D. Gold is chairman and chief executive officer of Biomed Realty, a publicly traded REIT specializing in acquiring and managing laboratory properties for lease to the life science industry. Mr. Gold also served as president of BioMed's privately held predecessor, Bernardo Property Advisors, Inc. He was a co-founder and served as president and as a director of Alexandria Real Estate Equities, Inc. He was managing partner of GoldStone Real Estate Finance and Investments, a partnership engaged in the real estate and mortgage business. He also served as assistant vice president of Commercial Real Estate for Northland Financial Company, a full service commercial property mortgage banker, and as Real Estate Investment Officer—Commercial Real Estate for John Burnham Company, a regional full service real estate company. He currently serves on the Campanile Foundation Board supporting San Diego State University.